Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Xuejing Aimee Wang"'
Autor:
Komal Jhaveri, Nadia Harbeck, Philippe Aftimos, Sung-Bae Kim, Xavier Pivot, Cristina Saura, Giuseppe Curigliano, Monica Casalnuovo, Xuejing Aimee Wang, Suzanne R.L. Young, Lillian Smyth, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 82:OT2-11
Background: The estrogen receptor (ER) is the key therapeutic target for ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Novel degraders of ER may overcome resistance to available endocrine therapy (ET) whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8e76dd3d7e2e814eb5ae0259abb5005
https://doi.org/10.1158/1538-7445.sabcs21-ot2-11-01
https://doi.org/10.1158/1538-7445.sabcs21-ot2-11-01
Autor:
Johanna C. Bendell, Volker Wacheck, Arantxa Uruñuela, Brian A. Moser, Xuejing Aimee Wang, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Charles S. Fuchs, Martin H. Voss, Alexander Drilon, Toni K. Choueiri, Todd M. Bauer, Andrew X. Zhu, James J. Harding
Purpose:Inhibition of the VEGFR-2 blocks angiogenesis and attenuates tumor growth, but cancers may evade this effect through activation of the hepatocyte growth factor receptor MET. Here we report results of the phase Ib/II study of ramucirumab, a mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac97243df440f786e7fc36749bd4ca0
https://doi.org/10.1158/1078-0432.c.6528086
https://doi.org/10.1158/1078-0432.c.6528086
Autor:
Johanna C. Bendell, Volker Wacheck, Arantxa Uruñuela, Brian A. Moser, Xuejing Aimee Wang, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Charles S. Fuchs, Martin H. Voss, Alexander Drilon, Toni K. Choueiri, Todd M. Bauer, Andrew X. Zhu, James J. Harding
Preclinical Data for Emibetuzumab and DC-101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed7b61fd28d7171e810b02390f658f7
https://doi.org/10.1158/1078-0432.22472048
https://doi.org/10.1158/1078-0432.22472048
Autor:
Johanna C. Bendell, Volker Wacheck, Arantxa Uruñuela, Brian A. Moser, Xuejing Aimee Wang, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Charles S. Fuchs, Martin H. Voss, Alexander Drilon, Toni K. Choueiri, Todd M. Bauer, Andrew X. Zhu, James J. Harding
Progression-free Survival in Gastric Cancer population, MET +23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4e12f5c6f2f6f870c86a8681fad24b
https://doi.org/10.1158/1078-0432.22472042.v1
https://doi.org/10.1158/1078-0432.22472042.v1
Autor:
Johanna C. Bendell, Volker Wacheck, Arantxa Uruñuela, Brian A. Moser, Xuejing Aimee Wang, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Charles S. Fuchs, Martin H. Voss, Alexander Drilon, Toni K. Choueiri, Todd M. Bauer, Andrew X. Zhu, James J. Harding
Exploratory Analysis of Different MET Expression Cut-offs in HCC Cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b4bf863d16629f1126bf0dbeb8a3aa
https://doi.org/10.1158/1078-0432.22472027
https://doi.org/10.1158/1078-0432.22472027
Autor:
Johanna C. Bendell, Volker Wacheck, Arantxa Uruñuela, Brian A. Moser, Xuejing Aimee Wang, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Charles S. Fuchs, Martin H. Voss, Alexander Drilon, Toni K. Choueiri, Todd M. Bauer, Andrew X. Zhu, James J. Harding
Supplementary figures titles and legends are placed in this document
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c7aaf7d89f3b7db134ae003b62dd6ba
https://doi.org/10.1158/1078-0432.22472021
https://doi.org/10.1158/1078-0432.22472021
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Table S1. Treatment emergent adverse events regardless of causality in {greater than or equal to}10% of patients; Table S2. Best Overall Response; Table S3. Reasons for Emibetuzumab Discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f81cf969170c12c35f49188178d97ea
https://doi.org/10.1158/1078-0432.22466984
https://doi.org/10.1158/1078-0432.22466984
Autor:
Johanna C. Bendell, Volker Wacheck, Arantxa Uruñuela, Brian A. Moser, Xuejing Aimee Wang, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Charles S. Fuchs, Martin H. Voss, Alexander Drilon, Toni K. Choueiri, Todd M. Bauer, Andrew X. Zhu, James J. Harding
Supplementary Tables 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0bf9a45880b36e2d6a20836105b167
https://doi.org/10.1158/1078-0432.22472018
https://doi.org/10.1158/1078-0432.22472018
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Treatment duration by patient and emibetuzumab dose for emibetuzumab monotherapy (A) and emibetuzumab + erlotinib (B).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69fb06598929ea674cc0d01332209f77
https://doi.org/10.1158/1078-0432.22466990
https://doi.org/10.1158/1078-0432.22466990
Autor:
Michaela Banck, James E. Wooldridge, Volker Wacheck, Jay Tuttle, Xuejing Aimee Wang, Tianle Hu, Brian Moser, P. Kellie Turner, Alain P. Algazi, Jonathan W. Goldman, Lee S. Rosen
Purpose: The MET/HGF pathway regulates cell proliferation and survival and is dysregulated in multiple tumors. Emibetuzumab (LY2875358) is a bivalent antibody that inhibits HGF-dependent and HGF-independent MET signaling. Here, we report dose escalat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004e241de2f3f7f6a81fbcc39945ee89
https://doi.org/10.1158/1078-0432.c.6526499
https://doi.org/10.1158/1078-0432.c.6526499